Publication: lron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferrin receptor
Loading...
Date
1997
Authors
Kemp, J.D.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
This review provides a perspective on the
potential utility of iron deprivation treatments as
components of cancer therapy. The perspective began to
develop with investigations of the selective inhibitory
effects on lymphocyte activation which were produced
by rnonoclonal antibodies against the transferrin
receptor. Those investigations led to the unexpected
discovery that such antibodies would produce synergistic
inhibition of lymphoid tumor growth in vitro when used
in combination with the iron chelator deferoxamine. The
perspective was further developed whea additional
studies in vivo indicated that combination iron
deprivation treatrnent could prevent initial tumor
outgrowth and cause regressions of established tumors in
the 38C13 rnurine lymphorna model. The anti-tumor
effects were accompanied by significant toxicities,
however, and the analysis of the causes of those
toxicities is now an irnportant issue. The opportunities
and problerns which these results present are interpreted
in the broader context of currently available information
conceming the anti-tumor effects of deferoxamine and
gallium nitrate in the pre-clinical and clinical settings,
and questions for future research are presented.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.